Biogen is making a strong move in immunology with a deal to acquire Human Immunology Biosciences (HI-Bio), a young startup whose lead program offers pipeline-in-a-product potential that could make it ...
On its face, Biogen’s May 2024 acquisition of Human Immunology Biosciences (HI-Bio) looks just like many other deals in the biopharma world. A $1.15 billion upfront payment to secure a phase 3-ready ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback